OraSure Technologies (NASDAQ:OSUR) has received a consensus rating of “Buy” from the six research firms that are currently covering the stock, MarketBeat reports. Two research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $21.50.
A number of research firms recently commented on OSUR. Zacks Investment Research upgraded OraSure Technologies from a “hold” rating to a “buy” rating and set a $23.00 price objective for the company in a research report on Friday, February 9th. Canaccord Genuity reiterated a “buy” rating and set a $24.00 price objective on shares of OraSure Technologies in a research report on Friday, February 2nd. BidaskClub cut OraSure Technologies from a “strong-buy” rating to a “buy” rating in a research report on Wednesday. Finally, ValuEngine upgraded OraSure Technologies from a “hold” rating to a “buy” rating in a research report on Friday, March 2nd.
Shares of OSUR stock traded up $0.10 during mid-day trading on Friday, hitting $16.89. The company’s stock had a trading volume of 1,036,265 shares, compared to its average volume of 579,911. OraSure Technologies has a 52-week low of $12.02 and a 52-week high of $23.01. The stock has a market capitalization of $1,029.73, a P/E ratio of 33.12, a P/E/G ratio of 5.00 and a beta of 1.60.
In related news, EVP Brian Smith sold 20,000 shares of the company’s stock in a transaction on Friday, February 16th. The stock was sold at an average price of $17.97, for a total transaction of $359,400.00. Following the completion of the sale, the executive vice president now owns 28,075 shares in the company, valued at $504,507.75. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Stephen S. Phd Tang sold 23,333 shares of the company’s stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $17.97, for a total value of $419,294.01. Following the completion of the sale, the director now owns 59,749 shares of the company’s stock, valued at approximately $1,073,689.53. The disclosure for this sale can be found here. 6.40% of the stock is currently owned by corporate insiders.
A number of institutional investors and hedge funds have recently modified their holdings of the business. BlackRock Inc. increased its position in OraSure Technologies by 2.7% in the fourth quarter. BlackRock Inc. now owns 7,729,515 shares of the medical instruments supplier’s stock worth $145,778,000 after buying an additional 201,251 shares in the last quarter. Millennium Management LLC increased its position in OraSure Technologies by 87.9% in the fourth quarter. Millennium Management LLC now owns 1,624,216 shares of the medical instruments supplier’s stock worth $30,633,000 after buying an additional 759,958 shares in the last quarter. Fred Alger Management Inc. purchased a new stake in OraSure Technologies in the fourth quarter worth about $20,415,000. Teachers Advisors LLC increased its position in OraSure Technologies by 9.0% in the fourth quarter. Teachers Advisors LLC now owns 965,464 shares of the medical instruments supplier’s stock worth $18,209,000 after buying an additional 79,886 shares in the last quarter. Finally, RTW Investments LP increased its position in OraSure Technologies by 64.0% in the fourth quarter. RTW Investments LP now owns 878,452 shares of the medical instruments supplier’s stock worth $16,568,000 after buying an additional 342,745 shares in the last quarter. Institutional investors and hedge funds own 93.67% of the company’s stock.
OraSure Technologies Company Profile
OraSure Technologies, Inc, together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, OSUR and DNAG. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests.
Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.